Article citationsMore>>

H. S. Kuehn, M. Y. Jung, M. A. Beaven, D. D. Metcalfe and A. M. Gilfillan, “Distinct PGE(2)-Responder and Non-Responder Phenotypes in Human Mast Cell Populations: ‘All or Nothing’ Enhancement of Antigen-Dependent Mediator Release,” Immunology Letters, Vol. 141, No. 1, 2011, pp. 45-54. doi:10.1016/j.imlet.2011.07.002

has been cited by the following article:

• TITLE: The 2-Series Eicosanoids in Cancer: Future Targets for Glioma Therapy?

  AUTHORS: Tiberiu Moga, Sunit Das

  KEYWORDS: Eicosanoids; Prostaglandins; Prostacyclins; Thromboxanes; Cancer; Glioma

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.1, February 27, 2013

  ABSTRACT: The 2-series eicosanoids are structurally related lipid-soluble hormones synthesized by cyclooxygenase enzymes from arachidonic acid. These compounds have well-established roles in the inflammatory response and the coagulation cascade. More recently, the eicosanoids have garnered attention for their potential roles in cancers of the lung, colon, breast, and brain. In this paper, we review the contributions of the different cyclooxygenase metabolites (i.e. prostaglandins, prostacyclins and thromboxanes) to cancer development, progression and recurrence, with special attention paid to their relevance to glioma biology. Our review suggests that 2-series eicosanoids merit further study as possible targets for therapy in patients with glioma.